MacroGenics traded at $3.00 this Friday March 13th, decreasing $0.12 or 3.85 percent since the previous trading session. Looking back, over the last four weeks, MacroGenics lost 76.47 percent. Over the last 12 months, its price rose by 35.14 percent. Looking ahead, we forecast MacroGenics to be priced at 2.91 by the end of this quarter and at 2.65 in one year, according to Trading Economics global macro models projections and analysts expectations.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.